Aastrom gets safety boost in US bone grafting trial
This article was originally published in Clinica
Aastrom Biosciences is to expand a US clinical trial of its bone regeneration technology to include a broader range of fractures, after the product met the study's safety endpoint.
You may also be interested in...
Advanced Medical Solutions said it will buy Raleigh Adhesive Coatings for £22m ($29m) in cash to strengthen its overall wound care business.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Lilly has launched a similar antibody product, but demand is expected to outpace supply for the foreseeable future.